Eisai Co Ltd

January 6, 2023

FDA approves Leqembi, new treatment for early-stage Alzheimer’s

[ad_1] The drug Leqembi may slightly slow cognitive decline in the early stages of the disease, but it comes with some safety risks. However, data suggests it holds more promise than the small number of other treatments available. [ad_2] Source link
November 29, 2022

Alzheimer’s drug may benefit some patients, new data shows

[ad_1] The drug lecanemab, made by Eisai and Biogen, also carries a risk of brain swelling and bleeding and should be investigated further, a report of the findings said. [ad_2] Source link
September 27, 2022

Alzheimer’s drug slows cognitive decline in key study

[ad_1] Biogen and Eisai reported the results of a large, late-stage clinical trial of lecanemab, a drug they are developing. [ad_2] Source link
Alzheimer’s drug slows cognitive decline in key study
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more